Evaluation of blood transfusion intervals in patients with ß-thalassemia major before and after administration of hydroxyurea
Phase 2
- Conditions
- Beta-thalassemia Major disease.Beta thalassemia
- Registration Number
- IRCT20180707040371N1
- Lead Sponsor
- Gorgan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
All patients are ß-thalassemia major who have been treated with blood transfusion, and after approval of the plan, they are treated monthly with hydroxyurea for 6 months.
Exclusion Criteria
Patients who do not tend to take oral medications
Patients with unstable hemodynamic status
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood transfusion intervals in patients. Timepoint: Frequency of blood transfusion in patients at baseline and then monthly for 6 months after administration of hydroxyurea. Method of measurement: cell blood count-patient files.;Hemoglobin total measurement. Timepoint: Hemoglobin total measurements at baseline and then monthly for 6 months after administration of hydroxyurea. Method of measurement: CBC.
- Secondary Outcome Measures
Name Time Method